Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | CPT1A | P50416 | 4/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530833 | 0.89 | HTR6 (0.59) | HTR6DRD2HTR2CHTR2BCPT1A | |
| SCHEMBL3532667 | 0.81 | HTR6 (0.57) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3532651 | 0.81 | HTR6 (0.53) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3532494 | 0.79 | HTR6 (0.52) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3589873 | 0.79 | HTR6 (0.53) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3531338 | 0.79 | HTR6 (0.53) | HTR6DRD2HTR2CHTR2B | |
| SCHEMBL3529115 | 0.79 | HTR6 (0.51) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3532673 | 0.79 | HTR6 (0.53) | HTR6DRD2HTR2CHTR2BPTGER4 | |
| SCHEMBL3948495 | 0.79 | HTR6 (0.88) | HTR6DRD2HTR2CHTR2B | |
| SCHEMBL3532291 | 0.78 | HTR6 (0.53) | HTR6DRD2HTR2CHTR2BPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | HTR6 1/4885DRD2 117/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.